786 related articles for article (PubMed ID: 3894520)
21. Identification of a unique T cell-derived lymphokine that primes macrophages for tumor cytotoxicity.
Kern DE; Grabstein KH; Okuno K; Schreiber RD; Greenberg PD
J Immunol; 1989 Dec; 143(12):4308-16. PubMed ID: 2687379
[TBL] [Abstract][Full Text] [Related]
22. Cellular interactions and the role of interleukin 2 in the expression and induction of immunity against a syngeneic murine sarcoma.
Chou T; Shu S
J Immunol; 1987 Sep; 139(6):2103-9. PubMed ID: 2957448
[TBL] [Abstract][Full Text] [Related]
23. Cell contact-mediated macrophage activation for antileishmanial defense. II. Identification of effector cell phenotype and genetic restriction.
Sypek JP; Panosian CB; Wyler DJ
J Immunol; 1984 Dec; 133(6):3351-7. PubMed ID: 6333458
[TBL] [Abstract][Full Text] [Related]
24. Macrophages as effector cells of protective immunity in murine schistosomiasis. VI. T cell-dependent, lymphokine-mediated, activation of macrophages in response to Schistosoma mansoni antigens.
James SL; Lazdins JK; Hieny S; Natovitz P
J Immunol; 1983 Sep; 131(3):1481-6. PubMed ID: 6350456
[TBL] [Abstract][Full Text] [Related]
25. Cellular origins and target cells of immunoregulatory factors in mice with disseminated histoplasmosis.
Deepe GS; Watson SR; Bullock WE
J Immunol; 1984 Apr; 132(4):2064-71. PubMed ID: 6230399
[TBL] [Abstract][Full Text] [Related]
26. Positively selected Lyt-2+ and Lyt-2- mouse T lymphocytes are comparable, after Con A stimulation, in release of IL 2 and of lymphokines acting on B cells, macrophages, and mast cells, but differ in interferon production.
Guerne PA; Piguet PF; Vassalli P
J Immunol; 1983 May; 130(5):2225-30. PubMed ID: 6187845
[TBL] [Abstract][Full Text] [Related]
27. Production of colony-stimulating factor by tumor cells and the factor-mediated induction of suppressor cells.
Tsuchiya Y; Igarashi M; Suzuki R; Kumagai K
J Immunol; 1988 Jul; 141(2):699-708. PubMed ID: 2968407
[TBL] [Abstract][Full Text] [Related]
28. Differential ability of tumor-unique and cross-reactive antigen(s) on two murine hepatoma cell lines to induce Lyt-1+2- T cells responsible for in vivo protective immunity.
Shima J; Yoshioka T; Kosugi A; Ogata M; Fujiwara H; Hamaoka T; Ueda S; Kato S
Biken J; 1987 Mar; 30(1):1-8. PubMed ID: 2445335
[TBL] [Abstract][Full Text] [Related]
29. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
Mokyr MB; Ye QW
Cancer Res; 1985 Oct; 45(10):4932-9. PubMed ID: 4027979
[TBL] [Abstract][Full Text] [Related]
30. Enhanced induction of tumor-specific Lyt-1+2- T cell-mediated protective immunity by in vivo administration of interleukin 1.
Izumi Y; Tsuchida T; Okuno K; Fujiwara H; Hamaoka T
Jpn J Cancer Res; 1985 Sep; 76(9):863-70. PubMed ID: 3932286
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice.
Fuyama S; Yamamoto H; Fujii Y; Arai S
Cancer Res; 1986 Nov; 46(11):5548-52. PubMed ID: 2428480
[TBL] [Abstract][Full Text] [Related]
32. Phenotypic characterization of human T lymphocyte populations producing macrophage-activating factor (MAF) lymphokines.
Biondi A; Roach JA; Schlossman SF; Todd RF
J Immunol; 1984 Jul; 133(1):281-5. PubMed ID: 6373929
[TBL] [Abstract][Full Text] [Related]
33. Murine tumor cell lysis by antibody-dependent macrophage-mediated cytotoxicity using syngeneic monoclonal antibodies.
Kawase I; Komuta K; Ogura T; Fujiwara H; Hamaoka T; Kishimoto S
Cancer Res; 1985 Apr; 45(4):1663-8. PubMed ID: 3978634
[TBL] [Abstract][Full Text] [Related]
34. Preparation and antitumor effect of macrophage activating factor (MAF) encapsulated in liposomes bearing a monoclonal anti-human melanoma (A375) antibody.
Watanabe Y; Uchida E; Higuchi M; Imai Y; Osawa T
J Biol Response Mod; 1987 Oct; 6(5):556-68. PubMed ID: 3316511
[TBL] [Abstract][Full Text] [Related]
35. Significance of suppressor macrophages for immunosurveillance of tumor-bearing mice.
Fujii T; Igarashi T; Kishimoto S
J Natl Cancer Inst; 1987 Mar; 78(3):509-17. PubMed ID: 2950265
[TBL] [Abstract][Full Text] [Related]
36. Lymphokine-mediated induction of cytolytic activity in a T cell hybridoma.
Kanagawa O; Chiller JM
J Immunol; 1985 Jan; 134(1):397-403. PubMed ID: 3917280
[TBL] [Abstract][Full Text] [Related]
37. Activation of tumoricidal properties in mouse macrophages by lymphokines encapsulated in liposomes.
Poste G; Kirsh R; Fogler WE; Fidler IJ
Cancer Res; 1979 Mar; 39(3):881-92. PubMed ID: 427777
[TBL] [Abstract][Full Text] [Related]
38. Lymphocyte induced macrophage cytotoxicity: characterization of the macrophage cytotoxicity-inducing lymphocyte.
Pels E; de Weger RA; den Otter W
Immunobiology; 1984 Jan; 166(1):84-95. PubMed ID: 6201434
[TBL] [Abstract][Full Text] [Related]
39. Analysis of the involvement of cells from donor and recipient mice in adoptive transfer of antitumor immunity.
Lee FH; Currie D; Hwang KM
Cancer Res; 1984 Dec; 44(12 Pt 1):5491-8. PubMed ID: 6208997
[TBL] [Abstract][Full Text] [Related]
40. Tumor cell-triggered macrophage-mediated suppression of the T-cell cytotoxic response to tumor-associated antigens. I. Characterization of the cell components for induction of suppression.
Ting CC; Rodrigues D
J Natl Cancer Inst; 1982 Oct; 69(4):867-72. PubMed ID: 6214653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
